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Abstract In order to investigate the biological function of
phosphatidylinositol-specific phospholipase C (PLC) we gener-
ated mutant mice by gene targeting. Homozygous inactivation of
PLCL3 is lethal at embryonic day 2.5. These mutants show poor
embryonic organization as well as reduced numbers of cells.
Identical phenotypes were recorded in homozygous mutants
generated from two independently targeted embryonic stem cell
clones. Heterozygous mutant mice, however, are viable and
fertile for at least two generations. We also showed that mouse
PLCL3 is expressed in unfertilized eggs, 3-cell and egg cylinder
stages of embryos. In conclusion, these results indicate that
PLCL3 expression is essential for early mouse embryonic
development.
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1. Introduction
Phosphatidylinositol-speci¢c phospholipase C (PLC) is im-
plicated to be activated in the mammalian oocyte at fertiliza-
tion [1]. Preincubation of mouse eggs with the PLC inhibitor,
U73122, greatly reduces their Ca2 responsiveness to acetyl-
choline as well as spermatozoa activation [2]. Blastocele for-
mation in the mouse is also inhibited by U73122 [3]. The
activated PLC generates inositol 1,4,5-trisphosphate (IP3)
which triggers a series of cytosolic Ca2 transients [4,5]. Intra-
cellular repetitive Ca2 oscillations are critical for egg activa-
tion and may contribute to the regulation of mouse preim-
plantational development [6,7]. The Ca2 release occurs
predominantly through the IP3 receptor from intracellular
stores [8,9]. Inhibition of the IP3 receptor by a monoclonal
antibody inhibits the Ca2 oscillations and blocks egg activa-
tion [4,10]. Acetylcholine, known to activate PLCL, could in-
duce repetitive Ca2 transients of mouse oocytes [11].
The human PLCL3 gene contains 31 exons and encodes a
1235 amino acid protein [12,13]. The X and Y regions com-
prise 170 and 260 amino acids, respectively. PLCL3 is the
most widely expressed member of the PLCL family [14,15].
The mouse PLCL3 gene is located on chromosome 19B [16]
and shows an overall 92% amino acid identity to the human
homolog [17]. PLCL3 in situ hybridization of rat embryos
shows expression in the neural tube at embryonic day (E) 8,
and in the thymus as well as lung tissues at E20 [18]. The
regulation of PLCL3 in early embryonic development has
not been studied. In an attempt to investigate the biological
function of PLCL3, we generated mutant mice by gene target-
ing.
2. Materials and methods
2.1. Construction of the targeting vector
A 1.9 kb 3P human PLCL3 cDNA fragment was used to screen a
129SV genomic library (Stratagene 946306, USA). The isolated clones
were analyzed by digestion with di¡erent restriction enzymes (XbaI,
EcoRI, EcoRV, SacI, BamHI, HindIII). Partial cleavage [19], poly-
merase chain reaction (PCR) analysis and DNA sequencing were per-
formed to determine the restriction map and genomic organization.
A 4 kb 5P SacI genomic fragment of the PLCL3 gene was cloned
into the SacI site of pBluescript II KS3 (Stratagene). A 1.4 kb 3P
SacI/HindIII genomic fragment of the PLCL3 gene was blunt-end
ligated into a T4 DNA polymerase treated XhoI site. Finally, neo-
mycin phosphotransferase expression cassette was blunt-end ligated in
sense orientation into the T4 DNA polymerase treated NotI site,
between the 5P and 3P fragments of PLCL3 genomic homologies.
This resulted in a deletion of a 4 kb genomic DNA fragment contain-
ing PLCL3 exons 11^17, as well as the introduction of an EcoRI and
an EcoRV site.
2.2. Generation of PLCL3 mutant mice
The embryonic stem (ES) cell line E14.1, derived from the mouse
strain 129/Ola, was cultured as described [20]. The targeting vector
was linearized with PvuII and electroporated into the ES cells. The
neomycin-resistant (G418) ES cell clones were isolated and analyzed
by Southern blotting. Two di¡erent clones were used for generation of
chimeras by injecting the targeted ES cells into C57BL blastocysts and
transferred to recipient mice [21]. Both attempts were successful and
the targeted ES cells contributed to the germ line of two chimeras.
2.3. Polymerase chain reaction
Routinely, neonates were genotyped by PCR using primers a, b,
and c. In selected cases, the genotype was veri¢ed by Southern blot
analyses, which were consistent with PCR results. All embryos were
genotyped by PCR ampli¢cation. Embryos or mouse tails were di-
gested with proteinase K. PCR ampli¢cations were performed using
three primers (a, b, and c) in a single reaction mixture for 35 cycles
(60 s at 94‡C, 90 s at 55‡C, 120 s at 72‡C). The common primer was
located in the 3P fragment for homologous recombination (a, 5P-
ttgtactcaaacacgcctgcgttga-3P). The primer for the wild type allele
was located in the deleted exon 17 (b, 5P-agcagctcagccgcatctaccctaa-
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3P). The mutant allele primer was in the neomycin resistance gene (c,
5P-cgctatcaggacatagcgttggcta-3P) (Fig. 1). In order to further amplify
and specify the signals a nested PCR was performed on 2 Wl aliquots
of the ¢rst PCR products using either primers aP (5P-acacgcctgcgtt-
gagctgcattggc-3P) and bP (5P-tgccagcttgttgccctcaacttcca-3P), or aP to-
gether with cP (5P-actgtgccttctagttgccagccat-3P), each located inside
the primers a, b and c. PCR products were resolved on 1% agarose
gels.
2.4. Culture of preimplantational embryos
Mating was achieved by caging paired heterozygous males and
females representing o¡spring from both chimeras respectively. Em-
bryos were collected on day 2.5 and cultured for 24 or 48 h [22].
Conditions for culturing encompassed M16 medium and a +37‡C
humidi¢ed incubator maintaining a 5% CO2 atmosphere. Individual
embryos were collected and suspended in lysis bu¡er before PCR
ampli¢cation.
2.5. Histology and immunohistochemistry
2.5.1. Embryos. Embryos from wild type mouse crossings were
collected and ¢xed overnight in 3% formalin. The ¢xative was em-
bedded in a drop of melted 2% agar and then cut into 1 mm3 blocks.
The agar blocks were dehydrated in ethanol and embedded in para⁄n
[23]. Mounted sections were stained for the presence of PLCL3 using
polyclonal antibody against the C-terminal portion of PLCL3 (sc-403,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) as primary anti-
body, and biotinylated anti-rabbit as secondary antibody. The immu-
noreaction was visualized with avidin-horseradish peroxidase and
DAB as the chromogen [24]. No positive staining was observed in
the absence of the primary antibody.
2.5.2. Tumor tissues. Tumor specimens were ¢xed in 4% para-
formaldehyde and embedded in para⁄n. For histological analysis,
5 Wm thick sections were stained with hematoxylin and eosin.
2.6. Western blot analysis
Western blotting was performed according to a modi¢ed method
[25]. Brie£y, 10 Wg of the total protein (quanti¢ed by protein assay kit,
Pierce, Rockford, IL, USA) was loaded on 4^15% SDS-polyacryl-
amide gradient gels, transferred to nitrocellulose membranes (Bio-
Rad, Hercules, CA, USA) and blocked with 5% non-fat milk for 1 h
at room temperature. The membranes were incubated overnight at
4‡C with anti-PLCL3 (above) diluted 1:1000. After rinsing and wash-
ing twice for 10 min with PBS containing 0.1% Tween 20, the ¢lters
were incubated for 1 h with a 1/1000 dilution of donkey anti-rabbit
IgG conjugated to horseradish peroxidase at room temperature. Sub-
sequently, the ¢lters were washed as above and developed using the
ECL Western blotting kit (Amersham, UK). After stripping (accord-
ing to the ECL Western blotting kit manual) the ¢lters were reprobed
with anti-actin monoclonal antibody (Boehringer Mannheim,
Germany). The ¢lters were scanned and target bands were quanti¢ed
with NIH Image software.
3. Results and discussion
In order to design the targeting construct, genomic DNA
clones encompassing the mouse PLCL3 gene were isolated
from a V phage library by probing with a human PLCL3
cDNA fragment. Eight positive clones were isolated and
phage DNA puri¢ed. Two overlapping clones spanning the
PLCL3 coding sequence were restriction mapped by partial
cleavage. The genomic structure of mouse PLCL3 was deter-
mined by DNA sequencing, restriction analysis and genomic
PCR. The organization of the mouse gene is similar to that of
the human, encompassing 31 exons spanning about 16 kb
(Fig. 1A). All analyzed exon-intron boundaries followed the
GT-AG intron donor-acceptor splice rule. The Pro¢le Scan
Program (http://isrec-insect.unil.ch/cgi-bin/Callmollusc.pl) re-
vealed two bipartite nuclear localization signals (aa 469^486
and aa 1100^1117). The amino acid sequence also contains the
X (aa 318^469) and Y (aa 590^707) domains [17]. The X
region comprises exons 10^13, and the Y region consists of
exons 15^21. The X and Y regions have been reported to be
essential for enzymatic activity [26].
The PLCL3 gene was disrupted in ES cells by a targeting
vector, which resulted in deleting exons 11^17, amino acid
sequence 338^681. Two thirds of the X and one third of the
Y region as well as one nuclear targeting sequence were re-
moved. The vector contained a neomycin resistance gene
£anked by 4.0 kb of genomic DNA upstream of exon 11 as
well as 1.4 kb downstream of exon 17 (Fig. 1A). Southern blot
analysis showed that ¢ve out of 200 neomycin resistant ES cell
clones carried a mutant PLCL3 allele. Two of these clones
(Fig. 1B) were used to generate chimeric mice, and both suc-
cessfully contributed to the germ line. The genotypes of the
mice were determined by PCR or Southern blotting.
No viable homozygous mutant (3/3) pups were identi¢ed
among 133 o¡spring from heterozygous (+/3) intercrosses
(Table 1). This suggests that inactivation of PLCL3 is lethal
to the embryo. We were able to produce heterozygous mutant
pups by breeding both male and female heterozygotes with
wild type mice, indicating that both paternal and maternal
sources of PLCL3 could sustain embryonic development. To
assess the consequences of the PLCL3 mutation on embryonic
development we analyzed embryos from heterozygote inter-
crosses at E17.5, E8.5, E3.5, and E2.5 (Table 1). Genotyping
was performed by nested PCR ampli¢cation (Fig. 1A,C). No
3/3 embryos were identi¢ed at E17.5 nor at E8.5 among 28
embryos. On embryonic day 3.5, 57 embryos were genotyped
and only one, which showed normal morphology for date,
was homozygous for the mutant allele. On E2.5 however, 14
of 99 embryos were identi¢ed as homozygous mutants. Ten of
these homozygotes showed abnormalities characterized by
poor embryonic organization and a substantial reduction of
cell numbers compared to wild type and heterozygous litter-
mates: mean number of cells 4.0 þ 0.6 (S.E.M.) vs. 7.5 þ 0.1
(S.E.M.) (P6 0.0001) (Table 1). Sixty-one of the 99 E2.5 mor-
ulas showed a heterozygous genotype and the remaining 24
represented wild types. Only two of the wild types and one
heterozygote showed abnormal morphology at E2.5. Addi-
tionally, we collected day 2.5 embryos from heterozygous
matings for culturing. Forty-two embryos were cultured for
24 h and both wild type and heterozygotes developed blasto-
cele cavities. Forty-¢ve embryos were cultured for 48 h, the
wild type and heterozygotes formed late expanded blastocysts.
The 11 mutants, however, failed to form blastocele cavities
and four appeared distorted at 48 h (Fig. 2). Homozygous
mutants generated from the two independently targeted ES
cell clones showed identical phenotypes. These results demon-
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Table 1
Genotypic and phenotypic analysis of neonates and embryos from
PLCL3 heterozygous intercrosses
Stage Total number Genotypea
+/+ +/3 3/3
Neonate 133 40 (0) 93 (1) 0
E17.5 5 2 (0) 3 (0) 0
E8.5 23 8 (0) 15 (1) 0
E3.5 57 16 (1) 40 (2) 1
E2.5 99 24 (1) 61 (2) 14 (10)
The embryos were collected on embryonic days 17.5, 8.5, 3.5, and 2.5.
Abnormal phenotypes encompassed poor embryonic organization and
reduced cell numbers in comparison with control littermates.
aNumber of abnormal individuals in parentheses.
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strate that homozygosity for the PLCL3 mutant allele results
in embryonic lethality at E2.5.
Immunohistochemical staining using a polyclonal PLCL3
antibody showed high expression PLCL3 in unfertilized wild
type mouse eggs as well as 3-cell stage embryos and egg cyl-
inders (Fig. 3). No PLCL3 immunoreactivity was observed in
primitive streak embryos.
The expression of PLCL3 protein in wild type and hetero-
zygous mice was investigated. Since the vast majority of ho-
mozygotes could not be identify beyond E2.5 the material was
too limited for Western blot analysis. We screened di¡erent
mouse tissues including brain, lung, heart, liver and kidney by
Western blot. The results demonstrate that PLCL3 protein is
widely expressed in various adult mouse tissues, and lung
tissue show the highest level (data not shown). Six wild type
and six heterozygous mice were killed. The proteins were ex-
tracted from each individual lung and used for Western blot.
PLCL3 protein of the expected size, 152 000, could be detected
on Western blot from both wild type and heterozygous mice.
The signal intensities were quanti¢ed with NIH Image soft-
ware and normalized with corresponding signals of actin.
Strikingly, the expression of PLCL3 protein in heterozygous
mice was signi¢cantly reduced (P6 0.05), about 50% com-
pared to that of wild type mice (Fig. 4). This result may
indicate that both PLCL3 alleles normally are responsible
for production of similar amounts of the protein. Under nor-
mal laboratory circumstances one allele can generate enough
PLCL3 protein to sustain the life of heterozygous mice.
Whether this reduced amount of PLCL3 would be su⁄cient
in more challenging conditions is unclear.
Heterozygous mice were apparently normal at young age.
However, at a mean age of 15.8 months (range 9.5^21.5),
eight of 50 PLCL3 +/3 mice, all derived from the ¢rst chi-
mera, were killed because of signs of distress. Necropsy
showed enlarged lymph nodes and spleen in all eight mice.
Histopathology revealed lymphomas in six of the animals.
All six lymphomas showed the same histological features re-
sembling human lymphoplasmacytoid lymphoma. One heter-
ozygous mouse revealed a pheochromocytoma and another
harbored a pancreatic microadenoma. Fourteen wild type
controls were killed at a mean age of 15.7 months (range
14^19.5) and four of them had the same type of lymphoid
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Fig. 1. Targeted disruption of the mouse PLCL3 gene. A: Genomic organization and targeting construct. Exons are depicted by ¢lled boxes.
Probe location for Southern blotting (probes 1, 2) and the PCR primers a, b and c, as well as the nested primers aP, bP and cP are shown. The
neomycin transferase gene linked to the phosphoglycerate kinase promoter (PGK-neo); EI, EcoRI; EV, EcoRV; S, SacI; H, HindIII; B, Bam-
HI. B: Southern blots showing homologous recombination at the PLCL3 locus for two of the targeted ES clones. The structure of the targeted
locus was veri¢ed on both sides. Genomic DNA was digested with EcoRI and hybridized with probe 1. The probe hybridized to a 12.5 kb
fragment derived from the wild type allele, or a 8.5 kb fragment from the allele with a correctly targeted replacement. Similarly, genomic DNA
digested with EcoRV and hybridization with probe 2 resulted in either a 13.5 kb fragment from the wild-type allele, or a 6.5 kb fragment from
the properly disrupted gene. C: Genotype analysis of embryos by PCR. Sizes of marker fragments (lane 1) are indicated. Primers aP, bP gener-
ate a 900 bp (wild type) PCR product, and primers aP, cP generate a 1200 bp (mutant) PCR product.
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tumor although in less severe stages of the disease. A larger
number of mice need to be investigated in order to fully
understand the nature of these tumors. Heterozygotes (mean
age 16 months) descending from our second chimera have not
developed lymphomas, suggesting that the observed tumors
are not speci¢cally related to the mutant PLCL3 allele.
The data presented here show that PLCL3 de¢cient embryos
su¡er from a developmental arrest at E2.5 indicating that
PLCL3 is essential for cellular proliferation at early embryonic
stages. The mutant phenotype was most likely caused by dis-
ruption of the PLCL3 gene rather than alterations elsewhere in
the ES cell genome since the o¡spring of the second chimera,
derived from independently targeted ES cells, showed the
same early embryonic lethality and presented no signs of lym-
phomas. Only 14% of E2.5 embryos presented a homozygous
mutant genotype, implying that some of the 3/3 mutants
disappeared before the ¢rst morphological event of di¡eren-
tiation. Alternatively, this unexpectedly low frequency could
constitute an underestimation due to PCR contamination.
Unfortunately, we had di⁄culties obtaining consistent results
from genotyping E1.5 embryos, again, mainly due to the lim-
ited DNA templates. High expression of PLCL3 was found in
wild type unfertilized eggs, 3-cell stage embryos and egg cyl-
inders. Substantial expression in eggs and morulae possibly
re£ects that PLCL3 function is essential for cleavage of zy-
gotes and early embryos. It seems likely that maternal sources
of PLCL3 are inadequate in sustaining embryos beyond the
4-cell stage since 10 out of 14 homozygous mutants encom-
passed four cells or fewer. Several laboratories have found
that inositol trisphosphate-induced Ca2 oscillations are asso-
ciated with developmental events, including egg activation and
fertilization [8,27,28]. Han et al. [29] observed that the blas-
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Fig. 3. Immunohistochemical detection of the PLCL3 protein in mouse embryos. A: Unfertilized egg. B: 3-cell embryo. C: Egg cylinder.
Fig. 2. Morphology of embryos. A: E2.5 embryos. The wild type and heterozygous mutant embryos showed the 8-cell stage. The mutant re-
mained at the 4-cell stage. B: E2.5 embryos cultured for 24 h. Both wild type and heterozygote developed blastocele cavities, but the mutant
failed to do so. C: E2.5 embryos cultured for 48 h. Wild type and heterozygotes had developed up to the expanded blastocysts. The mutant
appeared distorted and no blastocele cavity was formed.
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tomere stopped dividing after inhibition of PLC suggesting
that intracellular calcium release is mediated through a
PLC-dependent pathway. Becchetti and Whitaker reported
that lithium, an inhibitor of the phosphoinositide pathway,
blocked the cell cycle in sea urchin embryos at the 4-cell stage.
The block was reversed by IP3 indicating that phosphoinosi-
tide signaling is involved in the cell cycle of the early embryo
[30]. Both the tyrosine kinase and G-protein coupled path-
ways are believed to be involved in egg activation and preim-
plantational development [31]. De¢ciency studies of PLCL1,
L4 and PLCQ1 in mice have recently been performed [32^34].
Lethality before birth was not seen in PLCL1 or PLCL4 null
mice. Instead, impaired visual processing abilities and ataxia
were noted in PLCL4 null mice [32,33]. The PLCL1 mutant
pups developed epilepsy and showed failure to thrive [33].
Homozygous disruption of PLCQ1 resulted in embryonic le-
thality at E9 [34].
In conclusion, targeted disruption of PLCL3 was performed
in mice. Homozygous deletion of the PLCL3 gene leads to
preimplantational embryonic lethality, hence, PLCL3 cannot
be compensated by other isozymes or signaling pathways.
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Fig. 4. PLCL3 expression in lung tissue of wild type and heterozy-
gous mice analyzed by Western blot. The top panel shows an immu-
noblot with PLCL3 antibody and the lower with monoclonal actin.
Lanes 1^4 contain extracts from wild type tissue and lanes 5^8 from
heterozygous.
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